Introduction
============

Increased concentrations of reactive oxygen species (ROS) have been implicated in vascular diseases as well as diabetic vascular complications. Molecular oxygen, under electron reduction, forms superoxide anion (O~2~^−^), which serves as a progenitor for hydrogen peroxide (H~2~O~2~) and reduces bioactive nitric oxide (NO), leading to endothelial dysfunction ([@B01]). Also, the oxidation of biogenic amines by monoamine oxidase (MAO, types A and B) and semicarbazide-sensitive amine oxidase (SSAO) results in the production of the corresponding aldehyde, H~2~O~2~ and ammonia ([@B02],[@B03]). The degradation of H~2~O~2~ is rapidly metabolized by the Fenton reaction to the reactive hydroxyl radical and this leads to the onset and/or progression of cellular oxidative injury ([@B04]).

O~2~^−^ rapidly scavenges NO synthesized from L-arginine by nitric oxide synthase (NOS) to form peroxynitrite (ONOO^−^), which is a strong oxidant that can oxidize tetrahydrobiopterin (BH~4~), an important co-factor for NOS activity. Decreased BH~4~ concentrations alter the activity of endothelial NOS (eNOS) in blood vessels, cause enhanced uncoupling of eNOS, increase O~2~^−^ production and decrease NO in blood vessels, thus favoring production of ONOO^−^ ([@B05]). Another isoform with a relevant role is inducible NOS (iNOS), which is expressed in macrophages and other tissues ([@B06]). In addition to eNOS and iNOS, mitochondrial NOS (mtNOS), localized in the inner mitochondrial membrane, modulates respiratory rate and ATP synthesis ([@B07]).

The MAO enzyme is a flavoprotein associated with the outer membrane of mitochondria. There are two isoforms, MAO-A and MAO-B, distributed throughout the body, which are responsible for oxidative deamination of biogenic amines. Dopamine, tyramine and tryptamine are substrates for both isoforms, but MAO-A preferentially metabolizes noradrenaline and 5-hydroxytryptamine, whereas MAO-B preferentially metabolizes phenylethylamine ([@B02]).

The SSAO enzyme contains copper as a co-factor and is distributed in the plasma membrane of various tissues, present mainly in blood vessels, fibroblasts, adipocytes, and placenta. The SSAO enzyme metabolizes not only primary biogenic amines such as methylamine and aminoacetone, but also histamine, tyramine and dopamine. SSAO is also known as vascular adhesion protein-1 (VAP-1) and has been identified as one of the adhesion molecules involved in the leukocyte extravasation process ([@B03]).

There is evidence suggesting the involvement of MAO in neurodegenerative diseases, as well as an association between MAO and NO in the central nervous system ([@B08]). However, NO interference with MAO-A, MAO-B and SSAO kinetic parameters in peripheral arteries is poorly understood. Therefore, the aim of the present investigation was to study the correlation between total nitrite and nitrate (NOx) concentrations and the kinetic parameters of these enzymes in homogenates of human inferior mesenteric arteries obtained from non-diabetic and type 2 diabetic patients to better understand the mechanism of diabetes, a disease that affects many people.

Patients and Methods
====================

The human tissues were obtained at the Portuguese Oncology Institute of Coimbra from March 2008 to February 2009. The study was approved by the Institute\'s Medical Ethics Committee and all participants gave written informed consent. Only non-smoking patients participated in the study and none of the participants suffered from thyroid dysfunction, renal or liver disorders.

Segments of human inferior mesenteric arteries from 12 non-diabetic patients (61.1 ± 8.9 years old, 7 males and 5 females) and 12 type 2 diabetic patients (65.8 ± 6.2 years old, 8 males and 4 females) were obtained from individuals admitted for surgery. Both diabetic and non-diabetic patients in this study had sigmoid or rectum carcinoma and had not been subjected to neo-adjuvant therapeutics and whose primary option was surgery. The non-diabetic patients were selected according to the following criteria: blood glucose concentrations \<110 mg/dL, and absence of hypertension or renal disease (serum creatinine \<1.20 mg/dL). The patients with type 2 diabetes were selected according to the following criteria: blood glucose concentrations \> 110 mg/dL, HbA~1c~ \>6% and on treatment with an oral antidiabetic drug.

To avoid the effects of pathological anatomy, vessels of greatest caliber were selected, namely the inferior mesenteric artery, and only macroscopically healthy vessels were used. The arteries were placed in cole physiological saline solution and immediately transported to the laboratory where ±200 mg of each artery was homogenized in 10 mM sodium phosphate buffer, pH 7.4, at 4°C and the supernatant was obtained and stored at -80°C until further use.

The tissue homogenates were used for the measurement of NOx concentrations by the Griess reaction ([@B09]), using 1 g/L sulfanilamide from Sigma-Aldrich (USA), 25 g/L ortho-phosphoric acid from Merck (Germany), and 0.1 g/L N(-1-naphthyl) ethylenediamine from Sigma-Aldrich, as reagents. Nitrate concentration was measured as nitrite after enzymatic conversion by nitrate reductase from *Aspergillus* spp, and nitrite concentration was measured after deproteinization with zinc sulfate (300 g/L) at a 1:20 ratio (v/v) in order to obtain a final concentration of 15 g/L. The NOx values represent the sum of the nitrite and nitrate concentrations.

MAO-A, MAO-B and SSAO were determined by radiochemical methods using ^3^H-5-hydroxytryptamine creatinine sulfate (^3^H-5-HT) in the concentration range from 50 to 1000 µM as a specific substrate for MAO-A, 5 to 160 µM ^14^C-β-phenylethylamine hydrochloride (^14^C-β-PEA) as a specific substrate for MAO-B, and ^14^C-benzylamine (^14^C-BZ) in the concentration range from 50 to 1600 µM as a specific substrate for SSAO. For selective MAO-A and MAO-B inhibition, 0.1 mM selegiline was used as an MAO-B inhibitor and 1.0 µM clorgyline as an MAO-A inhibitor ([@B10]). All other reagents used were of analytical grade. The radioactivity released from the mixtures was measured with a Packard 2000 Tri-Carb liquid scintillation counter (Australia) and data were calculated in order to report the MAO-A, MAO-B and SSAO activities as nanomoles of substrate metabolized per mg protein per incubation hour (nmol·mg protein^−1^·h^−1^).

The results are reported as means ± SD. Statistical comparison of the groups was performed by the nonparametric Mann-Whitney test, and Pearson\'s correlation was used to test the correlations under study. The statistics were performed using the commercial GraphPad Prism software version 4.0 (USA), with the level of significance set at P \< 0.05.

Results
=======

In this study, no significant difference was found between the type 2 diabetic group and the non-diabetic group regarding the levels of nitrites (3.57 ± 2.58 *vs* 4.47 ± 2.17 nmol/mg protein, respectively) and nitrates (6.71 ± 3.33 *vs* 6.24 ± 3.44 nmol/mg protein, respectively) in homogenates of inferior mesenteric arteries. The mean NOx concentrations found in type 2 diabetic patients did not differ from that of non-diabetic patients (10.28 ± 4.61 *vs* 10.71 ± 4.32 nmol/mg protein, respectively).

[Table 1](#t01){ref-type="table"} shows the kinetic parameters of type 2 diabetic patients and controls. No significant difference was found between the two groups in *K*~m~ values for the three enzymes. There were differences in MAO-A and SSAO (*V*~max~) between the diabetic and non-diabetic groups but no significant difference for MAO-B (*V*~max~) between groups.

Table 1Kinetic parameters of MAO-A, MAO-B and SSAO (*V*~max~ and *K*~m~) in mesenteric artery homogenates from patients with type 2 diabetes and from non-diabetic patients.Type 2 diabetic patients (N = 12)Non-diabetic patients (N = 12)MAO-A*V*~max~ (nmol·mg protein^−1^·h^−1^)29.86 ± 11.7460.06 ± 21.43[\*](#TFN02t01){ref-type="table-fn"}*K*~m~ (µM)259.50 ± 101.80178.30 ± 99.17MAO-B*V*~max~ (nmol·mg protein^−1^·h^−1^)14.69 ± 7.3715.20 ± 3.03*K*~m~ (µM)86.63 ± 52.66100.50 ± 38.87SSAO*V*~max~ (nmol·mg protein^−1^·h^−1^)143.70 ± 62.41229.10 ± 46.28[\*](#TFN02t01){ref-type="table-fn"}*K*~m~ (µM)225.20 ± 167.10301.00 ± 127.30[^1][^2]

In type 2 diabetic patients, there was no correlation between NOx concentrations and the kinetic parameters of the three enzymes. No significant correlation was found between NOx concentrations and MAO-A (*K*~m~ and *V*~max~) in the non-diabetic patients. However, a positive correlation was obtained between NOx concentrations and MAO-B regarding *K*~m~ (Pearson r = 0.612, P = 0.034) and *V*~max~ (Pearson r = 0.593, P = 0.042). In contrast, there was a negative correlation between NOx concentrations and SSAO regarding *K*~m~ (Pearson r = -0.625, P = 0.029) and *V*~max~ (Pearson r = -0.754, P = 0.005; [Figure 1](#f01){ref-type="fig"}).

Figure 1Scatter diagrams showing the correlation between NOx concentrations (y-axis) and *K*~m~ or *V*~max~ (x-axis) of MAO-B (A) and SSAO (B) in mesenteric arteries of the control group (N = 12) determined by the Pearson method. NOx = total nitrite/nitrate concentrations; MAO-B = monoamine oxidase type B: SSAO = semicarbazide-sensitive amine oxidase.

Discussion
==========

In this study, we found: 1) no significant difference for NOx concentrations in the artery homogenates between the type 2 diabetic and non-diabetic groups; 2) in the diabetic group, NOx concentrations did not correlate with MAO-A, MAO-B or SSAO enzyme activities; 3) in the non-diabetic group, NOx did not correlate with MAO-A kinetic parameters (*K*~m~ and *V*~max~), but NOx was positively correlated with MAO-B kinetic parameters (*K*~m~ and *V*~max~) and negatively correlated with SSAO kinetic parameters (*K*~m~ and *V*~max~). This novel contribution may be useful to better understand the importance of NOx concentrations and biogenic amines in human vessels under physiological and pathophysiological conditions.

Endothelial cell dysfunction can release large amounts of ROS, including O~2~^−^, H~2~O~2~ and NO, that promote abnormal vascular growth, such as atherosclerosis in patients with diabetes mellitus ([@B11]). The ROS generated in physiological processes are closely regulated by enzymes such as NOS and nicotinamide adenine dinucleotide oxidase ([@B01]).

Oxidative stress is defined as an imbalanced redox state in which pro-oxidants overwhelm antioxidant capacity, resulting in increased ROS production, which plays a role in injury to cellular structures, including lipids, proteins and nucleic acids, as well as in the pathogenesis of various diseases such as cancer, diabetes, atherosclerosis, neurodegenerative diseases, and aging ([@B04],[@B06]).

Recent evidence indicates that the cytotoxic effect of NO is due to ONOO^−^, which is produced by the reaction between NO and O~2~^−^. ONOO^−^ interacts with lipids, DNA and proteins via direct or indirect oxidative reactions. These reactions produce modulations of cell signaling and induce cellular necrosis or apoptosis ([@B12]).

The innervation and NOS inhibition effects have been studied in the mesenteric arteries of the golden hamster using immunohistochemical and pharmacological methods, showing that the peripheral sympathetic nerves and NO regulate the functions of mesenteric arteries ([@B13]). In our study, we did not detect differences in NOx concentrations in mesenteric artery homogenates between the diabetic and non-diabetic groups. These findings suggest that a compensatory response to prolonged oxidative stress occurs, that the NO in the arteries is still sufficient and that the disease probably does not occur until these compensatory mechanisms fail ([@B05]). Indeed, a recent study from our group has indicated an increase in NOx concentrations in the serum of type 2 diabetic patients ([@B14]).

The direct interaction between the effects of NO on MAO activity in rat liver suggests that the generation of NO catalyzed by mtNOS is involved in the regulation of various mitochondrial functions ([@B15]). This enzyme may provide the basis for the regulation of cellular energy metabolism, oxygen consumption and ROS production. However, it is not possible to determine the NO synthesized by mtNOS using the Griess method ([@B05]).

It is known that in the gastrointestinal tract, the circulatory system and the liver, MAO-A and MAO-B regulate the deamination of amines from the diet, which exerts a potent vasopressor effect ([@B16]). However, the physiological relevance of SSAO in the gastrointestinal tract and blood vessels remains unclear. Biochemically, SSAO converts primary amines into potentially cytotoxic metabolites ([@B17]). The lack of correlation between NOx and SSAO kinetic parameters in the arteries of diabetic patients suggests that the damage to blood vessels can cause release of the SSAO protein into the circulation, as previously reported by our group ([@B14], [@B18]). Therefore, serum SSAO activity may be a useful biochemical marker for the control of vascular complications in diabetic patients ([@B17]−[@B19]).

The lack of correlation between the enzyme activities of MAO-A, MAO-B and SSAO with NOx concentrations in mesenteric arteries of diabetic patients and the correlation between MAO-B and SSAO with NOx concentrations in non-diabetic patients may be explained by the fact that NO down-regulates the expression of the Fenton reaction to prevent catalytic pro-oxidant reactions ([@B20]).

These results show that MAO-B and SSAO kinetic parameters are statistically correlated with NOx concentration in the inferior mesenteric arteries of non-diabetic patients, but these correlations were not observed in the arteries of diabetic patients, suggesting possible changes in vascular function in these arteries. This possibility must be further explored, namely by immunohistochemical analysis or by the study of other oxidative stress biomarkers.
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[^1]: Data are reported as means ± SD. MAO-A = monoamine oxidase type A; MAO-B = monoamine oxidase type B; SSAO = semicarbazide-sen-sitive amine oxidase.

[^2]: P \< 0.05 compared to diabetic patients (Mann-Whitney test).
